The medication Tecfidera increases numbers of regulatory B-cells.
While treatment of relapsing-remitting multiple sclerosis (RRMS) with Tecfidera (dimethyl fumarate) keeps relapse rates low, the details of immune changes induced by the drug are still evading scientists. A new study reported that the treatment increases the number of regulatory B-cells (Bregs), presenting a potential marker of treatment response.
The study “Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets“ was published in the journalNeuroimmunology & Neuroinflammation.
Recent studies have shown that Tecfidera decreased certain immune cells, of both B-, and T-cell type in MS patients. Studies have also indicated that this class of drugs affects the signaling through IL-10, a key regulator of immune responses. This anti-inflammatory cytokine is most often released by regulatory B-, and T-cells (Tregs).
|Read Full Article: MS Therapy Tecfidera Might Exert its Actions by Increasing Specific B-cells – Multiple Sclerosis News Today|